Cargando…

Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial

This randomized, open-label, multicenter, parallel study imitating real-world clinical practice assessed the effect of switching to weekly teriparatide in patients with glucocorticoid-induced osteoporosis (GIO) with a lumbar spine/proximal femur bone mineral density (BMD) T-score ≤ −2.0 or ≤−1.0 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nanki, Toshihiro, Kawazoe, Mai, Uno, Kiyoko, Hirose, Wataru, Dobashi, Hiroaki, Kataoka, Hiroshi, Mimura, Toshihide, Hagino, Hiroshi, Kono, Hajime
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820936/ https://www.ncbi.nlm.nih.gov/pubmed/36615091 http://dx.doi.org/10.3390/jcm12010292

Ejemplares similares

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

Management of glucocorticoids-induced osteoporosis: role of teriparatide
por: Migliaccio, Silvia, et al.
Publicado: (2009)

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
por: Lau, Arthur N, et al.
Publicado: (2010)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yuan, Chuanjian, et al.
Publicado: (2023)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Bisphosphonates and glucocorticoid-induced osteoporosis: cons
por: Lems, Willem F., et al.
Publicado: (2015)

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
por: Sugimoto, Toshitsugu, et al.
Publicado: (2017)

Utility of radius bone densitometry for the treatment of osteoporosis with once-weekly teriparatide therapy
por: Nakayama, Harumi, et al.
Publicado: (2018)

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
por: Mori, Satoshi, et al.
Publicado: (2022)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
por: Bauss, Frieder, et al.
Publicado: (2006)

A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05
por: Hagino, H., et al.
Publicado: (2021)

New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide
por: Tanaka, Sakae, et al.
Publicado: (2014)

Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007)

Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases
por: Kaneko, Kaichi, et al.
Publicado: (2022)

Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
por: Weigl, Moritz, et al.
Publicado: (2021)

A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis
por: Hagino, H., et al.
Publicado: (2019)

Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis
por: Dore, Robin K
Publicado: (2013)

Influence of immunosuppressive therapy on longitudinal changes in anti-SARS-CoV-2 spike protein antibodies after two doses of mRNA vaccines in patients with rheumatic diseases
por: Kawazoe, Mai, et al.
Publicado: (2023)

Safety of SARS-CoV-2 mRNA vaccines and effects of immunosuppressive drugs on adverse reactions in patients with rheumatic diseases
por: Kawazoe, Mai, et al.
Publicado: (2023)

Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study
por: Muraoka, Sei, et al.
Publicado: (2021)

Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis
por: Fan, Guiyong, et al.
Publicado: (2020)

The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis
por: Ouyang, YuLong, et al.
Publicado: (2021)

Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012)

Therapy of Osteoporosis in Men with Teriparatide
por: Cusano, Natalie E., et al.
Publicado: (2011)

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
por: Murphy, Daniel R, et al.
Publicado: (2012)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Teriparatide for osteoporosis: importance of the full course
por: Lindsay, R., et al.
Publicado: (2016)

Treatment of osteoporosis with teriparatide: The Slovenian experience
por: Kocjan, Tomaz, et al.
Publicado: (2021)

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
por: Sugimoto, T., et al.
Publicado: (2013)

Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk
por: Ifuku, Emiko, et al.
Publicado: (2019)

Subtrochanteric Femoral Insufficiency Fracture in Woman on Bisphosphonate Therapy for Glucocorticoid-Induced Osteoporosis
por: Bush, Lisabeth A., et al.
Publicado: (2016)

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
por: Jakob, F, et al.
Publicado: (2012)

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
por: Jakob, F, et al.
Publicado: (2012)

Effectiveness of Osteoporosis Drug in Postmenopausal Women with Spinal Compression Fracture: Combined Consecutive Therapy of Teriparatide and Raloxifene versus Bisphosphonate Single
por: Shin, Chang Jin, et al.
Publicado: (2016)

Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
por: Moriwaki, K., et al.
Publicado: (2017)

Comparative Effects of Teriparatide and Risedronate in Glucocorticoid-Induced Osteoporosis in Men: 18-Month Results of the EuroGIOPs Trial
por: Glüer, Claus-C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tala1mcjf9g9djqqa849j0kmsp